Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

GlaxoSmithKline Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (243)
ARTG (106)
Australian public assessment report (AusPar) (42)
Prescription medicine registration (22)
Designation or determination (5)
Prescription medicine decision summary (3)
Prescription medicine evaluation (3)
Face mask cancellation (1)

Date

2026 (1)
2025 (26)
2024 (13)
2023 (18)
2022 (61)
2021 (12)
2020 (59)
2019 (30)
2018 (27)
2017 (24)
2016 (11)
2015 (49)
2014 (21)
2013 (9)
2012 (6)
2011 (4)
2010 (7)
2009 (3)
2008 (6)
2007 (4)
2006 (3)
2005 (4)
2004 (1)
2003 (3)
2002 (1)
2001 (1)
2000 (3)
1999 (1)
1998 (5)
1997 (4)
1995 (1)
1991 (6)

Search

Sponsor content

425 result(s) found, displaying 251 to 260

SALBUTAMOL-AS salbutamol (as sulfate) 2.5mg/2.5mL inhalation solution ampoule Cancelled under s30(1)(c) of the Act

17 January 2018

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
SALBUTAMOL-AS salbutamol (as sulfate) 5mg/2.5mL inhalation solution ampoule Cancelled under s30(1)(c) of the Act

17 January 2018

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
SKB STERILE DILUENT for reconstitution of lyophilised vaccine multidose injection vial Cancelled under s30(1)(c) of the Act

16 January 2018

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
SKB WATER FOR INJECTION ampoule Cancelled under s30(1)(c) of the Act

16 January 2018

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
SKB STERILE DILUENT for reconstitution of Mencevax injection vial Cancelled under s30(1)(c) of the Act

16 January 2018

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
SKB STERILE DILUENT for reconstitution of lyophilised vaccine multidose injection ampoule Cancelled under s30(1)(c) of the Act

16 January 2018

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
TRELEGY ELLIPTA (GlaxoSmithKline Australia Pty Ltd)

9 January 2018

Prescription medicine registration

Active ingredients: fluticasone furoate, umeclidinium bromide, vilanterol trifenatate.
AREPANRIX H5N1 pandemic influenza vaccine suspension for injection 2.5mL vial with adjuvant emulsion 2.5mL vial Cancelled under s30(1)(c)

27 December 2017

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
PANDEMRIX H1N1 pandemic influenza vaccine split virion inactivated AS03 adjuvanted 0.5 mL dose Cancelled under s30(1)(c)

27 December 2017

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
INCRUSE ELLIPTA umeclidinium (as bromide) 62.5 microgram powder for inhalation (211601)

8 July 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for INCRUSE ELLIPTA umeclidinium (as bromide) 62.5 microgram powder for inhalation.

Pages

First page
Previous page
…
Page 22
Page 23
Page 24
Page 25
Current page 26
Page 27
Page 28
Page 29
Page 30
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.